Federal Register / Vol. 75, No. 239 / Tuesday, December 14, 2010 / Notices 77885 

Genetics and Visual Function Branch, is 

seeking statements of capability or 

interest from parties interested in 

collaborative research to further 

develop, evaluate, or commercialize the 

use of nitisinone (NTBC) for 

oculocutaneous albinism or as a 

treatment for increasing pigmentation in 

the eyes, hair and/or skin of patients. 

Please contact Alan Hubbs, PhD at 301– 

594–4263 or hubbsa@mail.nih.gov for 

more information. 

Modulators of Survival Motor Neuron 

Production 

Description of Invention: This 

technology discloses compounds that 

modulate the amount of Survival Motor 

Neuron protein (SMN). Low levels of 

SMN protein are associated with Spinal 

Muscular Atrophy (SMA), which 

constitutes a group of inherited diseases 

that cause progressive muscle 

degeneration leading to death. 

Consequently, therapeutic inventions 

have focused on increasing SMN protein 

levels. This invention discloses novel 

arylthiazolyl piperidines which are 

shown to be modulators of SMN 

production. This invention also 

discloses methods of treating SMA by 

administering SMN protein modulators. 

Applications: Therapeutic 

developments for Spinal Muscular 

Atrophy. 

Advantages: Small molecule (series of 

analogs can be derived in search of 

improved performance). 

Development Status: 

• Pre-clinical; no animal data. 

• In vitro data available. 

Market: Muscular dystrophy. 

Inventors: Juan Jose Marugan 

(NHGRI–NCGC); Wei Zheng (NHGRI– 

NCGC); Noel Southall (NHGRI–NCGC); 

Jingbo Xiao (NHGRI–NCGC); Steve Titus 

(NHGRI–NCGC); Elliot Androphy 

(University of Massachusetts Medical 

School); Jonathan Cherry (University of 

Massachusetts Medical School). 

Patent Status: U.S. Provisional 

Application No. 61/323,963 filed 14 

April 2010 (HHS Reference No. E–109– 

2010/0–US–01). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Steven H. 

Standley, PhD; 301–435–4074; 

sstand@mail.nih.gov. 

Collaborative Research Opportunity: 

The NIH Chemical Genomics Center 

(NCGC), National Human Genome 

Research Institute, is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize these SMN modulator 

compounds. Please contact Dr. Juan 

Marugan at maruganj@mail.nih.gov for 

more information. 

Use of Sterculic Acid To Treat 

Choroidal Neovascularization 

Description of Invention: Sterculic 

acid is a naturally occurring 

cyclopropene acid present in kapok 

seed oil, cottonseed oil, and in the seeds 

of the Sterculia foetida tree. Sterculic 

acid has been reported to be a nonspecific inhibitor of stearoyl-Co 

desaturase (SCD), which has been 

implicated in several disease states, 

including cardiovascular disease, 

obesity, non-insulin-dependent diabetes 

mellitus, skin disease, hypertension, 

neurological diseases, immune 

disorders and cancer (Ntambi JM, J. 

Lipid Res., 1999, 40(9):1549–1558). NIH 

investigators have recently discovered 

that sterculic acid inhibits the 

neovascularization of the chick 

chorioallantonic membrane 

demonstrating that this compound 

exhibits a potent anti-angiogenic 

activity. Further, the NIH investigators 

have shown that sterculic acid inhibits 

the formation of choroidal 

neovascularization in the retina of laser 

treated rats. These results suggest that 

sterculic acid possesses anti-angiogenic 

effect likely through regulating genes 

involved in the angiogenic process. 

The present invention is directed to 

methods of using sterculic acid for the 

treatment of inflammation, in particular, 

7-ketocholesterol mediated 

inflammation, 7-ketocholesterol 

cytotoxicity, or unregulated 

angiogenesis. Diseases mediated by 7- 

ketocholesterol-induced inflammation 

and 7-ketocholesterol cytotoxicity 

include atherosclerosis age-related 

macular degeneration, and Alzheimer’s 

disease. Diseases mediated by 

unregulated angiogenesis include 

certain cancers and age-related macular 

degeneration. Also disclosed are 

methods of treating atherosclerosis or 

Alzheimer’s disease using sterculic acid. 

Applications: Therapeutics for 

inflammation, in particular, 

atherosclerosis, age-related macular 

degeneration, and Alzheimer’s disease 

Development Status: Early stage in 

vitro and animal model data. 

Inventors: Ignacio R. Rodriguez et al. 

(NEI). 

Patent Status: U.S. Provisional 

Application No. 61/358,485 filed 25 Jun 

2010 (HHS Reference No. E–092–2010/ 

0–US–01). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Suryanarayana 

Vepa, PhD, J.D.; 301–435–5020; 

vepas@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Eye Institute (NEI), 

Laboratory of Retinal Cell and 

Molecular Biology, is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize sterculic acid, and its 

derivatives for the treatment of diseases 

related to angiogenesis or mediated by 

7-ketocholesterol-induced 

inflammation. Please contact David L. 

Whitmer, Technology Development 

Coordinator, NEI, at 301–496–4876 or 

whitmerd@mail.nih.gov for more 

information. 

Dated: December 8, 2010. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2010–31320 Filed 12–13–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Software System for Quantitative 

Assessment of Vasculature in Three 

Dimensional Images 

Description of Invention: 

This invention offered for licensing 

and further development is a software 

system that provides the capability of 


srobinson on DSKHWCL6B1PROD with NOTICES
77886 Federal Register / Vol. 75, No. 239 / Tuesday, December 14, 2010 / Notices 

efficiently extracting, visualizing and 

quantifying three dimensional vascular 

networks from medical and basic 

research images. Deregulation of 

angiogenesis plays a major role in a 

number of human diseases, most 

notably cancer. A substantial increase in 

the research effort in this field over the 

past decade has deepened the 

understanding of the angiogenic 

process. However, the lack of methods 

and software to quantitatively assess 

vasculature in patients has considerably 

hampered the ability to directly study 

the angiogenesis process, as well as to 

discover and develop new therapeutics 

to modulate angiogenesis. The present 

invention provides new semi-automated 

computer algorithms, statistical 

methods and user friendly visualization 

tools for rapid and intuitive quantitative 

evaluation of vasculature in three 

dimensional data sets obtained through 

non-invasive imaging techniques such 

as MRI, CT–Scans, confocal microscopy, 

microCT, etc. The methods and software 

embodied in this invention provide a 

three dimensional quantitative 

capability in the clinic as a vascular 

diagnostic tool and in basic research 

projects to evaluate changes in vascular 

network systems. 

Applications: 

• Medical research for studying 

angiogenesis and tumor vasculature. 

• Potential applications in clinical 

studies and diagnostics. 

• Discovery and development of antiangiogenesis agents with application to 

cancer. 

• Possible application to diseases 

other than cancer, such as those related 

to the lymphatic system, the pulmonary 

airway, the kidney filtration system. 

Development Status: 

• The invention is fully developed. 

• The software will be readily 

available if so requested. 

Inventors: Enrique Zudaire, 

Christopher Kurcz, Yanling Liu (NCI). 

Patent Status: HHS Reference No. E– 

261–2010/0—Software. Patent 

protection is not being pursued for this 

technology. 

Licensing Status: Available for 

licensing. 

Licensing Contacts: 

• Uri Reichman, PhD, MBA; 301– 

435–4616; UR7a@nih.gov. 

• Michael Shmilovich, Esq.; 301– 

435–5019; ShmilovichM@mail.nih.gov. 

Compounds That Treat Malaria and 

Prevent Malaria Transmission 

Technology Summary: The invention 

offered for licensing relates to 

therapeutic compounds and related 

pharmaceutical compositions that can 

be used in the prevention and treatment 

of malaria infection. More specifically, 

the invention is drawn to compounds 

that can kill malaria gametocytes to 

block malaria transmission and treat 

malaria infection in the non-erthtrocytic 

stages, as well as therapeutic uses of 

these molecules to prevent or slow the 

transmission of plasmodium organisms 

between mammals and eliminate or 

prevent infection in mammal. 

Furthermore, the compounds of the 

invention are tricyclic compounds 

where the side rings may be 5–7 

membered rings (preferably 6- 

membered), and the center ring may be 

6–8 membered ring (preferably 7- 

membered). Also preferable structures 

are ones in which the side rings are aryl 

rings while the center ring is cycloalkyl 

ring. The compounds of the invention 

have been identified by integrating 

quantitative high-throughput screening 

(qHTS) with genetic mapping and in 

vivo oocyst formation assay. 

Applications: Prevention and 

treatment of malaria infections. 

Inventors: Xin-zhuan Su and Jing 

Yuan (NIAID). 

Patent Status: International Patent 

Application No. PCT/US2010/047019 

filed August 27, 2010. Priority 

Application 61/237,417 filed August 27, 

2009. (HHS Reference No. E–283–2009). 

Licensing Status: Available for 

licensing. 

Licensing Contacts: 

• Uri Reichman, PhD, MBA; 301– 

435–4616; UR7a@nih.gov. 

• Michael Shmilovich, Esq.; 301– 

435–5019; ShmilovichM@mail.nih.gov. 

A Universal Antigen Delivery Platform 

for Enhanced Immune Response 

Description of Invention: The present 

invention relates to use of the rotavirus 

NSP2 octamer as a universal antigen 

delivery platform for presenting a high 

density of neutralizing epitopes to the 

immune system, a strategy for boosting 

antigen immunogenicity. This 

application is advanced by the welldefined structural and biochemical 

properties of the octamer, its high 

stability at a broad range of pH, 

temperature and ionic stability, and its 

ease of purification (one step) under 

nondenaturing conditions. Long 

conformationally-dependent antigens 

are readily mounted onto the platform 

by fusion to the C-terminus of NSP2, a 

region of the NSP2 protein positioned 

on the exposed surface of the octamer. 

The platform can be expressed in and 

purified from prokaryotic and 

eukaryotic systems. 

This technology can be used for rapid 

production of subunit vaccines against a 

wide range of infectious agents. 

Additional uses of the technology 

include the generation of delivery 

platforms with mounted short peptide 

antigens for use in cancer 

immunotherapy, production of specific 

antisera to conformationally and 

nonconformationally-dependent 

antigens for research purposes, and 

development of epitope targets and 

short peptide-antigen presentation 

platforms for diagnostic assays. 

Applications: 

• Vaccines against pathogens. 

• Cancer vaccines. 

• Antigen-specific antisera. 

• Multivalent targets in diagnostic 

assays. 

Advantages: 

• Octameric platform is stable, 

efficiently expressed, and easily 

purified by a single step method. 

• Enables the display of multivalent 

conformation-dependent epitopes. 

• Effective platform for short peptides 

as well as long polypeptides. 

Development Status: Proof-of-concept 

experiments have shown that the 

octamer mounted with short peptides or 

long multivalent polypeptides retains its 

structural and biophysical features and 

is highly effective in presenting foreign 

antigens to the immune system. Ease of 

purification and final protein yields of 

the short or long peptide antigenmounted NSP2 octamers were 

comparable suggesting that the platform 

accommodates a large range of antigen 

sizes. The NSP2-platform also served as 

an adjuvant, significantly enhancing 

immunity of the mounted peptide. 

Inventors: John T. Patton (NIAID); 

Zenobia F. Taraporewala (NIAID). 

Relevant Publications: 

1. P Schuck et al. Rotavirus 

nonstructural protein NSP2 selfassembles into octamers that undergo 

ligand-induced conformational changes. 

J Biol Chem. 2001 Mar 30;276(13):9679– 

9687. [PubMed: 11121414] 

2. H Jayaram et al. Rotavirus protein 

involved in genome replication and 

packaging exhibits a HIT-like fold. 

Nature. 2002 May 16;417(6886):311– 

315. [PubMed: 12015608] 

3. Z Taraporewala et al. Rotavirus 

NSP2 octamer as an epitope-mounting 

platform. Abstract, 23rd Annual 

Meeting of the American Society for 

Virology, 2004. 

4. K Kearney et al. Cell-line-induced 

mutation of the rotavirus genome alters 

expression of an IRF3-interacting 

protein. EMBO J. 2004 Oct 

13;23(20):4072–4081. [PubMed: 

15372078] 

Patent Status: U.S. Patent Application 

No. 11/293,654 filed 02 Dec 2005 (HHS 

Reference No. E–322–2004/0–US–02). 

Licensing Status: Available for 

licensing. 


srobinson on DSKHWCL6B1PROD with NOTICES
Federal Register / Vol. 75, No. 239 / Tuesday, December 14, 2010 / Notices 77887 

Licensing Contact: Kevin W. Chang, 

PhD; 301–435–5018; 

changke@mail.nih.gov. 

Dated: December 1, 2010. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2010–31319 Filed 12–13–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel; Sardinia. 

Date: January 19, 2011. 

Time: 3 p.m. to 6 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institute on Aging, 

Gateway Building, 7201 Wisconsin Avenue, 

Suite 2C212, Bethesda, MD 20892, 

(Telephone Conference Call) 

Contact Person: Jeannette L. Johnson, PhD, 

Scientific Review Officer, National Institutes 

on Aging, National Institutes of Health, 7201 

Wisconsin Avenue, Suite 2C212, Bethesda, 

MD 20892, 301–402–7705, 

JOHNSONJ9@NIA.NIH.GOV. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel; Development 

and Maintenance of an Aged Rodent Tissue 

Bank. 

Date: January 27, 2011. 

Time: 1:30 p.m. to 2:30 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institute on Aging, 

Gateway Building, 7201 Wisconsin Avenue, 

Suite 2C212, Bethesda, MD 20892, 

(Telephone Conference Call) 

Contact Person: Bita Nakhai, PhD, 

Scientific Review Officer, Scientific Review 

Branch, National Institute on Aging, Gateway 

Bldg., 2C212, 7201 Wisconsin Avenue, 

Bethesda, MD 20814, 301–402–7701, 

nakhaib@nia.nih.gov. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel; Development 

and Maintenance of a Multigenotypic Aged 

Rat Colony. 

Date: January 27, 2011. 

Time: 12 p.m. to 1:30 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institute on Aging, 

Gateway Building, 7201 Wisconsin Avenue, 

Suite 2C212, Bethesda, MD 20892, 

(Telephone Conference Call) 

Contact Person: Bita Nakhai, PhD, 

Scientific Review Officer, Scientific Review 

Branch, National Institute on Aging, Gateway 

Bldg., 2C212, 7201 Wisconsin Avenue, 

Bethesda, MD 20814, 301–402–7701, 

nakhaib@nia.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.866, Aging Research, 

National Institutes of Health, HHS) 

Dated: December 8, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–31322 Filed 12–13–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the 

National Advisory Council on Aging. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Council on Aging. 

Date: January 25–26, 2011. 

Closed: January 25, 2011, 3 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, C Wing, 

Conference Room 6, Bethesda, MD 20892. 

Open: January 26, 2011, 8 a.m. to 12:45 

p.m. 

Agenda: Call to order and reports from the 

Director; discussion of future meeting dates; 

consideration of minutes from last meeting; 

reports from the Task Force on Minority 

Aging Research, the Working Group on 

Program, and Council of Councils; council 

speaker Dr. Eileen Crimmins; and Program 

Highlights. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, C Wing, 

Conference Room 6, Bethesda, MD 20892. 

Closed: January 26, 2011, 12:45 p.m. to 

1:15 p.m. 

Agenda: To review and evaluate the 

Intramural Research Program. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, C Wing, 

Conference Room 6, Bethesda, MD 20892. 

Contact Person: Robin Barr, PhD, Director, 

National Institute on Aging, Office of 

Extramural Activities, Gateway Building, 

7201 Wisconsin Avenue, Bethesda, MD 

20814, (301) 496–9322, barrr@nia.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

Information is also available on the 

Institute’s/Center’s home page: http:// 

www.nih.gov/nia/naca/, where an agenda 

and any additional information for the 

meeting will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.866, Aging Research, 

National Institutes of Health, HHS) 

Dated: December 8, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–31321 Filed 12–13–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 


srobinson on DSKHWCL6B1PROD with NOTICES